# A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

> **NCT04135495** · PHASE2 · COMPLETED · sponsor: **Eloxx Pharmaceuticals, Inc.** · enrollment: 17 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** ELX-02
- **DRUG:** Ivacaftor

## Key facts

- **NCT ID:** NCT04135495
- **Lead sponsor:** Eloxx Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-25
- **Primary completion:** 2022-10-03
- **Final completion:** 2022-10-03
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2022-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04135495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04135495, "A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04135495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*